Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_assertion type Assertion NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_head.
- NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_assertion description "[The authors investigated the impact of the genetic polymorphisms cytochrome P450 (CYP) family 2, subfamily D, polypeptide 6, allele 10 (CYP2D6 10) and CYP family 2, subfamily C, polypeptide 19, allele 2, 3 (CYP2C19 2, 3) on disease recurrence in patients with breast cancer who received adjuvant tamoxifen and evaluated the impact of those polymorphisms on endometrial thickness, bone mineral density (BMD), and serum total cholesterol levels.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_provenance.
- NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_assertion evidence source_evidence_literature NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_provenance.
- NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_assertion SIO_000772 19156902 NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_provenance.
- NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_assertion wasDerivedFrom befree-20140225 NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_provenance.
- NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_assertion wasGeneratedBy ECO_0000203 NP282630.RAvyxbTnQYE15MdFYUM2bOa921u9kBSckVlSYJLgPUl2A130_provenance.